|
1
|
Pezzoli G and Zini M: Levodopa in
Parkinson's disease: From the past to the future. Expert Opin
Pharmacother. 11:627–635. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Richardson JR and Hossain MM: Microglial
ion channels as potential targets for neuroprotection in
Parkinson's disease. Neural Plast. 2013:5874182013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
AlDakheel A, Kalia LV and Lang AE:
Pathogenesis-targeted, disease-modifying therapies in Parkinson
disease. Neurotherapeutics. 11:6–23. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang G, Pan J and Chen SD: Kinases and
kinase signaling pathways: Potential therapeutic targets in
Parkinson's disease. ProgNeurobiol. 98:207–221. 2012.
|
|
5
|
Whitton PS: Inflammation as a causative
factor in the aetiology of Parkinson's disease. Br J Pharmaco.
150:963–976. 2007. View Article : Google Scholar
|
|
6
|
Dutta G, Zhang P and Liu B: The
lipopolysaccharide Parkinson's disease animal model: Mechanistic
studies and drug discovery. Fundam Clin Pharmacol. 22:453–464.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hines DJ, Choi HB, Hines RM, Phillips AG
and MacVicar BA: Prevention of LPS-induced microglia activation,
cytokine production and sickness behavior with TLR4 receptor
interfering peptides. PLoS One. 8:e603882013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pereira MD, Ksiazek K and Menezes R:
Oxidative stress in neurodegenerative diseases and ageing. Oxid Med
Cell Longev. 2012:7963602012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Imai Y, Venderova K, Park DS, Cai H and
Schmidt E: Animal models of Parkinson's disease. Parkinsons Dis.
2011:3643282011.PubMed/NCBI
|
|
10
|
Chang Q and Wang XL: Effects of chiral
3-n-butylphthalide on apoptosis induced by transient focal cerebral
ischemia in rats. Acta Pharmacol Sin. 24:796–804. 2003.PubMed/NCBI
|
|
11
|
Dong GX and Feng YP: Effects of NBP on
ATPase and anti-oxidant enzymes activities and lipid peroxidation
in transient focal cerebral ischemic rats. Zhongguo Yi Xue Ke Xue
Yuan Xue Bao. 24:93–97. 2002.PubMed/NCBI
|
|
12
|
Li L, Zhang B, Tao Y, Wang Y, Wei H, Zhao
J, Huang R and Pei Z: DL-3-n-butylphthalide protects endothelial
cells against oxidative/nitrosative stress, mitochondrial damage
and subsequent cell death after oxygen glucose deprivation in
vitro. Brain Res. 1290:91–101. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang JZ, Chen YZ, Su M, Zheng HF, Yang
YP, Chen J and Liu CF: DL-3-n-butylphthalide prevents oxidative
damage and reduces mitochondrial dysfunction in an MPP(+)-induced
cellular model of Parkinson's disease. Neurosci Lett. 475:89–94.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tian Y, Zhang Y, Zhang R, Qiao S and Fan
J: Resolvin D2 recovers neural injury by suppressing inflammatory
mediators expression in lipopolysaccharide-induced Parkinson's
disease rat model. Biochem Biophys Res Commun. 460:799–805. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang W, Chen YH, Liu H and Qu HD:
Neuroprotective effects of piperine on the
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's
disease mouse model. Int J Mol Med. 36:1369–1376. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cebrián C, Loike JD and Sulzer D:
Neuroinflammation in Parkinson's disease animal models: A cell
stress response or a step in neurodegeneration? Curr Top Behav
Neurosci. 22:237–270. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kannarkat GT, Boss JM and Tansey MG: The
role of innate and adaptive immunity in Parkinson's disease. J
Parkinsons Dis. 3:493–514. 2013.PubMed/NCBI
|
|
18
|
Tai W, Ye X, Bao X, Zhao B, Wang X and
Zhang D: Inhibition of Src tyrosine kinase activity by squamosamide
derivative FLZ attenuates neuroinflammation in both in vivo and in
vitro Parkinson's disease models. Neuropharmacology. 75:201–212.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou HF, Liu XY, Niu DB, Li FQ, He QH and
Wang XM: Triptolide protects dopaminergic neurons from
inflammation-mediated damage induced by lipopolysaccharide
intranigral injection. Neurobiol Dis. 18:441–449. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu B and Hong JS: Role of microglia in
inflammation-mediated neurodegenerative diseases: Mechanisms and
strategies for therapeutic intervention. J Pharmacol Exp Ther.
304:1–7. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peng Y, Zeng X, Feng Y and Wang X:
Antiplatelet and antithrombotic activity of L-3-n-butylphthalide in
rats. J Cardiovasc Pharmacol. 43:876–881. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yan CH, Feng YP and Zhang JT: Effects of
dl-3-n-butylphthalide on regional cerebral blood flow in right
middle cerebral artery occlusion rats. Zhongguo Yao Li Xue Bao.
19:117–120. 1998.PubMed/NCBI
|
|
23
|
Liu CL, Liao SJ, Zeng JS, Lin JW, Li CX,
Xie LC, Shi XG and Huang RX: DL-3n-butylphthalide prevents stroke
via improvement of cerebral microvessels in RHRSP. J Neurol Sci.
260:106–113. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang L, Yu WH, Wang YX, Wang C, Zhao F,
Qi W, Chan WM, Huang Y, Wai MS, Dong J and Yew DT:
DL-3-n-butylphthalide, an anti-oxidant agent, prevents neurological
deficits and cerebral injury following stroke per functional
analysis, magnetic resonance imaging and histological assessment.
Curr Neurovasc Res. 9:167–175. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li J, Li Y, Ogle M, Zhou X, Song M, Yu SP
and Wei L: DL-3-n-butylphthalide prevents neuronal cell death after
focal cerebral ischemia in mice via the JNK pathway. Brain Res.
1359:216–226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yan CH, Feng YP and Zhang JT: Effects of
dl-3-n-butylphthalide on regional cerebral blood flow in right
middle cerebral artery occlusion rats. Zhongguo Yao Li XueBao.
19:117–120. 1998.
|
|
27
|
Peng Y, Xing C, Lemere CA, Chen G, Wang L,
Feng Y and Wang X: L-3-n-butylphthalide ameliorates
beta-amyloid-induced neuronal toxicity in cultured neuronal cells.
Neurosci Lett. 434:224–229. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang XH, Lu G, Hu X, Tsang KS, Kwong WH,
Wu FX, Meng HW, Jiang S, Liu SW, Ng HK and Poon WS: Quantitative
assessment of gait and neurochemical correlation in a classical
murine model of Parkinson's disease. BMC Neurosci. 13:1422012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim EK and Choi EJ: Pathological roles of
MAPK signaling pathways in human diseases. Biochim Biophys Acta.
1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Corrêa SA and Eales KL: The role of p38
MAPK and its substrates in neuronal plasticity and
neurodegenerative disease. J Signal Transduct. 2012:6490792012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cuadrado A and Nebreda AR: Mechanisms and
functions of p38 MAPK signalling. Biochem J. 429:403–417. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cargnello M and Roux PP: Activation and
function of the MAPKs and their substrates, the MAPK-activated
protein kinases. Microbiol Mol Biol Rev. 75:50–83. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kaul T, Credle J, Haggerty T, Oaks AW,
Masliah E and Sidhu A: Region-specific tauopathy and
synucleinopathy in brain of the alpha-synuclein overexpressing
mouse model of Parkinson's disease. BMC Neurosci. 12:792011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang Q, Du X, He X, Yu Q, Hu K,
Breitwieser W, Shen Q, Ma S and Li M: JNK-mediated activation of
ATF2 contributes to dopaminergic neurodegeneration in the MPTP
mouse model of Parkinson's disease. Exp Neurol. 277:296–304. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Crocker CE, Khan S, Cameron MD, Robertson
HA, Robertson GS and Lograsso P: JNK inhibition protects dopamine
neurons and provides behavioral improvement in a rat
6-hydroxydopamine model of Parkinson's disease. ACS Chem Neurosci.
2:207–212. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hwang CJ, Lee HP, Choi DY, Jeong HS, Kim
TH, Lee TH, Kim YM, Moon DB, Park SS, Kim SY, et al: Inhibitory
effect of thiacremonone on MPTP-induced dopaminergic
neurodegeneration through inhibition of p38 activation. Oncotarget.
7:46943–46958. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhu JH, Gusdon AM, Cimen H, Van Houten B,
Koc E and Chu CT: Impaired mitochondrial biogenesis contributes to
depletion of functional mitochondria in chronic MPP+
toxicity: Dual roles for ERK1/2. Cell Death Dis. 3:e3122012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Amiri E, Ghasemi R and Moosavi M: Agmatine
protects against 6-OHDA-induced apoptosis, and ERK and Akt/GSK
disruption in SH-SY5Y cells. Cell Mol Neurobiol. 36:829–838. 2016.
View Article : Google Scholar : PubMed/NCBI
|
